Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) just unveiled an announcement.
Lumos Diagnostics has made significant strides in FY25, transitioning from an early-stage business to an emerging global diagnostics company. The company has expanded its distribution partnerships, notably with Henry Schein and PHASE Scientific, and has secured reimbursement for FebriDx on the U.S. Medicare fee schedule. A successful CLIA waiver trial for FebriDx has been completed, with the application submitted to the FDA, potentially expanding the U.S. market significantly. A new distribution agreement with PHASE Scientific could be worth up to US$317 million, marking a major milestone for Lumos. The company remains well-funded, with a focus on disciplined execution and expanding its product’s clinical use, supported by BARDA.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid, point-of-care diagnostic technologies, offering customized assay development and manufacturing services to aid healthcare professionals in diagnosing and managing medical conditions. The company is focused on the global commercialization of its flagship product, FebriDx, and has a growing market presence, particularly in the U.S.
Average Trading Volume: 6,424,343
Technical Sentiment Signal: Buy
Current Market Cap: A$184.7M
See more data about LDX stock on TipRanks’ Stock Analysis page.